Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

11.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.8K
Coagulation01:06

Coagulation

1.6K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.0K
Recombinant DNA01:09

Recombinant DNA

104.6K
Overview
104.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C seropositivity in HIV-negative children with severe haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Editorial.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

DDI and liver tests in HIV-1 seropositive haemophiliacs.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The knowledge and perception of factor concentrate in persons with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Inhibitors of factor VIII and IX.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Journal of thrombosis and haemostasis : JTH·2014

Related Experiment Video

Updated: Mar 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Recombinant coagulation factor products.

D B Brettler1

  • 1New England Hemophilia Center, The Medical Center of Central Massachusetts, 119 Belmont Street, Worcester, MA 01605-2892, USA.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 24, 2016
PubMed
Summary
This summary is machine-generated.

New recombinant coagulation factors, including factor VIII (FVIII) and factor VIIa (FVIIa), are advancing treatment for bleeding disorders. These innovative therapies show promise for patients with inhibitor antibodies and are nearing human trials.

Keywords:
coagulation disorderhaemophiliarecombinant factor concentrate

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Area of Science:

  • Biotechnology
  • Hematology
  • Pharmacology

Background:

  • Coagulation factor concentrates are crucial for treating bleeding disorders.
  • Traditional manufacturing methods have limitations.
  • Recombinant technology offers new possibilities for producing these factors.

Purpose of the Study:

  • To review novel recombinant coagulation factor concentrates.
  • To discuss their current applications and ongoing clinical trials.
  • To highlight potential uses and adverse effects of these new products.

Main Methods:

  • Review of current literature on recombinant coagulation factors.
  • Analysis of clinical trial data for FVIII, FVIIa, and FIX concentrates.
  • Discussion of manufacturing technologies and product profiles.

Main Results:

  • Recombinant factor VIII (FVIII) concentrates are widely licensed.
  • A B domain-deleted FVIII concentrate is nearing availability.
  • Recombinant factor VIIa (FVIIa) is in Phase III trials for inhibitor patients.
  • Recombinant factor IX (FIX) shows success in animal models and is entering human trials.

Conclusions:

  • Recombinant technology is significantly advancing the development of coagulation factor concentrates.
  • These novel products offer improved treatment options for bleeding disorders.
  • Further research and clinical evaluation are essential to fully understand their efficacy and safety profiles.